| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press.
EDITORIAL |
Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?
Affiliations of authors: Departments of Hematology (IPT) and Medical Oncology (MB), Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
Correspondence to: Ivo P. Touw, PhD, Department of Hematology, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands (e-mail: i.touw@erasmusmc.nl).
| The first 150 words of the full text of this article appear below. |
Granulocyte colony-stimulating factor (G-CSF), the major cytokine involved in the control of neutrophil production, is used in the clinic for treatment of congenital and acquired neutropenias and to reduce febrile neutropenia before or during courses of intensive cytoreductive therapy. In addition, healthy stem cell donors are treated with G-CSF for mobilization of hematopoietic stem cells in the peripheral blood. Recent studies have uncovered novel roles for G-CSF in myocardial regeneration following cardiac infarction (1–3) and in ameliorating programmed cell death in neuronal cells caused by acute ischemic stroke, thereby reducing the volume of the brain infarct (4). Thus, it may be anticipated that the therapeutic application of G-CSF will increase considerably in the near future, making careful and timely risk assessment of vital importance.
In this issue of the Journal, Hershman et al. (5) report a twofold increased risk of secondary myelodysplasia
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 196-205.
J Natl Cancer Inst 2007 99: 181.
This article has been cited by other articles:
|
|
 |
|
  H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling In Reply Oncologist, December 1, 2007; 12(12): 1465 - 1466. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Patt, Z. Duan, S. Fang, G. N. Hortobagyi, and S. H. Giordano Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk J. Clin. Oncol., September 1, 2007; 25(25): 3871 - 3876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Warren and M. L. Brown Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy J Natl Cancer Inst, July 4, 2007; 99(13): 1050 - 1050. [Full Text] [PDF]
|
|